Acta dermato-venereologica最新文献

{"title":"Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study.","authors":"Nidia Planella-Fontanillas, Emilio Berna-Rico, Ignasi Figueras-Nart, Jorge Spertino, Lluís Dols Casanova, María Elena Gatica Ortega, Vicente Expósito-Serrano, Miguel Antonio Lasheras Pérez, Mercedes Rodríguez Serna, José M Mascaró, Gemma Melé-Ninot, Pedro Mercader-García, Francisco José Navarro Triviño, Fátima Tous Romero, Marta Elosua-González, Jorge Magdaleno-Tapial, Amparo Pérez Ferriols, Trinidad Montero-Vilchez, José Ignacio Torné Gutiérrez, Fernando Gallardo, David Pesqué, Ramon M Pujol, Esther Serra-Baldrich, Ana M Giménez-Arnau","doi":"10.2340/actadv.v106.adv-2026-0485","DOIUrl":"10.2340/actadv.v106.adv-2026-0485","url":null,"abstract":"<p><p>Chronic spontaneous urticaria (CSU) remains difficult to manage in patients refractory to antihistamines and omalizumab. Although dupilumab has recently been approved and incorporated into international guidelines, real-world evidence remains limited, particularly in treatment-refractory populations. We conducted a multicentre ambispective cohort study across 16 Spanish hospitals including adults with CSU, with or without concomitant chronic inducible urticaria, treated with dupilumab and followed for ≥4 weeks. The primary outcome was well-controlled disease within 24 weeks (Urticaria Control Test ≥12 and Urticaria Activity Score over 7 days≤6). Fiftyone patients were included; 92.0% had previously received omalizumab. At week 24, 69.7% (23/33) achieved well-controlled disease and 39.4% (13/33) complete control. Among patients with available week-52 data, 90.5% (19/21) and 61.9% (13/21), respectively, achieved these outcomes. Concomitant therapy use declined from 94.1% at baseline to 55.6% at week 52. Among omalizumab-experienced patients evaluable at week 24, dupilumab response was lower in prior nonresponders than in those with at least partial response to omalizumab (40% vs 85%, p=0.011). Atopic comorbidities were associated with greater UAS7 reduction (p=0.018). Dupilumab was well tolerated, with mostly mild adverse events. In routine clinical practice, dupilumab provides effective disease control in patients with difficult-totreat CSU, including most omalizumab-experienced individuals.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13334162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148389620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.","authors":"Martin Metz, Karsten Weller, Sonja Ständer, Abigail Nesbeth, Donia Bahloul, Simmi Wiggins","doi":"10.2340/actadv.v106.adv-2025-0123","DOIUrl":"10.2340/actadv.v106.adv-2025-0123","url":null,"abstract":"<p><p>Chronic prurigo (CPG), including prurigo nodularis (PN), is a neuroimmune-inflammatory skin condition characterized by persistent itching and fibrotic lesions. PN commonly affects older adults (>55 years) and imposes substantial disease burden, necessitating effective disease control. Prurigo Control Test (PCT) is the first validated, patient reported, disease control assessment test for PN/ CPG. To ensure broad accessibility and utility, cultural and linguistic adaptation of PCT is essential. We present the first comprehensive translation initiative of PCT into 18 widely spoken languages, beyond its original German and English versions: Arabic/Chinese (Simplified)/ Chinese (Traditional)/Czech/Danish/Dutch/Finnish/ French/Hebrew/Icelandic/Italian/Japanese/Korean/ Norwegian/Portuguese/Spanish/Swedish/Turkish. We followed best translation practices recommen ded by ISPOR, EMA and FDA ‒ conceptual analysis, forward/backward translation, author review, cognitive interviews, proofreading and finalization. The availability of PCT in multiple languages facilitates its global applicability and empowers physicians/caregivers/patients to assess the PN/CPG control using PCT in their preferred language, thereby enhancing implementation of this test across diverse clinical and cultural settings. The goal of translating this academically developed test while ensuring broader demographic representation (ages 18-80, diverse educational and occupational backgrounds) is to facilitate meaningful conversations between physicians and patients and optimize treatment decisions while transcending language barriers. To our knowledge, PCT is the first disease control assessment test specifically designed for PN/CPG to undergo such extensive linguistic adap-tation, contributing to the advancement of global dermatological assessment.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13334163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148389636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.","authors":"Philip Curman, Henning Olbrich, Khalaf Kridin, Diamant Thaçi, Ralf J Ludwig","doi":"10.2340/actadv.v106.adv-2026-0643","DOIUrl":"10.2340/actadv.v106.adv-2026-0643","url":null,"abstract":"<p><p>Chronic spontaneous urticaria (CSU) has been associated with psychiatric comorbidity, but previous studies have often been limited by cross-sectional designs, reverse causation and surveillance bias. We conducted a retrospective matched cohort study using the TriNetX US Collaborative Network to evaluate the risk of incident psychiatric disorders after CSU diagnosis. Adults with newly diagnosed CSU and no prior psychiatric diagnosis were propensity score matched 1 : 1 to non-CSU controls. Outcomes were depression, reaction to severe stress and adjustment disorders, schizophrenia and suicidal ideation or suicide attempts during 3 years of follow-up. After matching, 98,785 individuals were included in each group. CSU was associated with a modestly increased risk of reaction to severe stress and adjustment disorders (hazard ratio 1.15, 95% confidence interval 1.09-1.22), consistent across sensitivity analyses. No consistent increased risk was observed for depression, schizophrenia or suicide-related outcomes. A complementary asso ciation analysis including patients with pre-existing psychiatric disease reproduced previously reported associations with depression and stress-related disorders. These findings suggest that CSU is not broadly associated with incident psychiatric disease but is linked to a small, reproducible increase in stress-related psychiatric morbidity.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13334492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148389668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An 8-year-old Girl with Multiple Whitish Dots on the Hair Shaft: A Quiz.","authors":"Jiamin Xu, Yanjun Tang, Xiqing Li, Fengjie Liu","doi":"10.2340/actadv.v106.adv-2026-0421","DOIUrl":"10.2340/actadv.v106.adv-2026-0421","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Congenital Subcutaneous Tumour of the Scalp in a Child: A Quiz.","authors":"Haruka Mukai, Yuto Yamamura, Kazuyasu Fujii, Shunya Usui, Atsushi Otsuka","doi":"10.2340/actadv.v106.adv-2026-0401","DOIUrl":"10.2340/actadv.v106.adv-2026-0401","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study.","authors":"Patrícia Moreira-Gomes, Ruben Costa, Bárbara Granja, Filomena Azevedo, Carmen Lisboa","doi":"10.2340/actadv.v106.adv-2026-0636","DOIUrl":"10.2340/actadv.v106.adv-2026-0636","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Facial Lesion with Cord-like Induration and Ring-like Appearance on MRI: A Quiz.","authors":"Muneto Maeda, Yuto Yamamura, Kazuyasu Fujii, Shunya Usui, Atsushi Otsuka","doi":"10.2340/actadv.v106.adv-2026-0678","DOIUrl":"10.2340/actadv.v106.adv-2026-0678","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13321352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study.","authors":"Xinchen Ke, Yixia Gao, Jundong Huang, Ji Li, Aike Wu, Wei Shi","doi":"10.2340/actadv.v106.adv-2026-0453","DOIUrl":"10.2340/actadv.v106.adv-2026-0453","url":null,"abstract":"<p><p>Long-standing alopecia areata is a therapeutically challenging subgroup lacking robust evidence regarding Janus kinase (JAK) inhibitors. This retrospective, single-centre study evaluated the efficacy and safety of baricitinib, tofacitinib or ritlecitinib in patients with current alopecia areata episodes lasting ≥8 years, treated between February 2021 and December 2025. Among 41 screened patients, 31 met the inclusion criteria (mean age 24.6±10.1 years; mean episode duration 12.7±4.6 years). The mean baseline SALT score was 62.8±30.2, with 64.5% of patients presenting a baseline SALT score ≥50. At week 24 (n=29), 27.6% and 24.1% of patients achieved absolute SALT scores ≤20 and ≤10, respectively. Relative improvements (SALT30, SALT50 and SALT80) were observed in 48.3%, 31.0% and 24.1% of patients. Treatment discontinuation occurred in 58.1% (18/31) of patients, primarily driven by a lack of efficacy (66.7% of these discontinuations). The most frequent adverse events were folliculitis (22.6%) and acne (12.9%). While the overall therapeutic response to JAK inhibitors remains limited in long-standing alopecia areata, a subset achieves clinically meaningful hair regrowth, supporting their use as a viable treatment option.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on: \"The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma\".","authors":"Marit B Veierød, Morten Valberg, Adele C Green, Flavie Perrier","doi":"10.2340/actadv.v106.adv-2026-0741","DOIUrl":"10.2340/actadv.v106.adv-2026-0741","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Widespread Erythematous Vesiculobullea: A Quiz.","authors":"Xiaoting Song, Dong Lan, Fang Liu","doi":"10.2340/actadv.v106.adv-2025-0240","DOIUrl":"10.2340/actadv.v106.adv-2025-0240","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}